Clinical trial NCT01844648: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients
Official title: A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sialorrhea (Excessive Drooling)
Keywords: Parkinson's disease
Sialorrhea
Tropicamide
Non-motor symptoms
Thin strip delivery
Lead sponsor: NeuroHealing Pharmaceuticals Inc.
Sponsor class: INDUSTRY
Collaborators: name: Michael J. Fox Foundation for Parkinson's Research
First posted: 2013-05-01
Enrollment: 30
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To study the safety and efficacy of tropicamide 1 mg intra-oral slow dissolving muco-adhesive thin films compared to placebo to reduce hypersalivation in PD patients manifesting sialorrhea complaints.

Detailed description: This is a double-blind, placebo-controlled, randomized, crossover, multicentre study comparing intra-oral slow dissolving muco-adhesive thin films containing tropicamide 1 mg or Placebo. Patients will receive each treatment twice daily (1 h after breakfast and 1 h after lunch) for 1-week.

Patients will be evaluated for eligibility during the 14-day screening period. Those patients meeting all entry criteria at baseline will be randomized (1:1) to receive first tropicamide followed by placebo films or vice versa. Patients will return for regularly scheduled visits at Weeks 1 and 3 or at early discontinuation.

Eligibility criteria: Inclusion criteria:

* Patients with idiopathic Parkinson's disease, according to the UK Brain Bank criteria.
* Patients complaining of drooling, with a score of at least 6 points in the SCS-PD scale.
* Patients above 30 years old.
* Patients with Hoehn \& Yahr score between I-IV.
* Male or non-pregnant female. Females of child-bearing potential will be required to have undergone a pregnancy test with negative results prior to entry to the study and agree to use contraceptive measures for the duration of the study.
* Patients must have used the same antiparkinsonian medications and at the same dose for the last month. No changes in the medication for PD are expected during the study.

Exclusion criteria:

* Pregnant women.
* Patients with a secondary parkinsonian syndrome, parkinsonism-plus syndromes, heredodegenerative disorders or benign parkinsonism.
* Patients with a diagnosis of major depression or psychosis according to the DSM-IV.
* Patients with MMSE score equal to or lower than 24.
* Patients with a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months.
* Patients with hallucinations.
* Patients with a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including hypertension that is not well-controlled, asthma, chronic obstructive pulmonary disease (COPD) and Type I diabetes.
* Patients with a second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method.
* Patient with a neoplastic disorder, which is either currently active or has been in remission for less than one year.
* Patients with a history or a current diagnosis of HIV, or tests positive for Hepatitis B or C antibodies, or Hepatitis B surface antigen
* Patients who have participated in a previous clinical trial within 30 days of entry into the study (screening visit) or have received treatment with any investigational compound within 30 days.
* Patients with hypersensitivity to atropine or other anticholinergic drugs.
* Patients who have experienced adverse effects as a result of taking anticholinergic drugs.
* Patients who are receiving any anticholinergic drug or an anticholinesterase agent.
* Patients who started or changed the dose of any of the following medications in the previous week: tricyclic antidepressants, monoamine oxidase-A inhibitors, antipsychotics, benzodiazepines, opioids, antihistamines, carbamazepine, NSAIDs.
* Patients with significant dental/oral pathology.
* Patient with any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in a diagnostic laboratory test.
* Patients with closed-angle Glaucoma or those at high risk of suffering it after treatment with anticholinergic agents.
* Patients with Prostatic Adenoma.
* In the judgment of the Clinical Investigator, the patient is likely to be non-compliant or uncooperative during the study.

Primary outcomes:
measure: modified Teachers Drooling Scale (% responding)
timeFrame: one week
Secondary outcomes:
measure: modified Teachers Drooling Scale (mean)
timeFrame: one week
measure: Sialorrhea Clinical Scale for Parkinson's Disease (mean)
timeFrame: one week
measure: UPDRS Part II sialorrhea item (mean)
timeFrame: one week
measure: Visual Analg Scale
timeFrame: one week
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital de la Salpêtrière
state: Cedrex 13
city: Toulouse
country: France
facility: Hôpital Paul de Viguier
state: Cedrex 9
city: Bordeaux
country: France
facility: Hôpital Haut Lévêque
state: Pessac
Study officials:
affiliation: NeuroHealing Pharmaceuticals Inc.
name: Elkan R Gamzu, PhD
role: STUDY_DIRECTOR
References: